Safety and efficacy of the combination of pegylated interferon-&#945;2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Hjorth-Hansen, H; Stentoft, J; Richter, J; Koskenvesa, P; Höglund, M; Dreimane, A; Porkka, K; Gedde-Dahl, T; Gjertsen, B T; Gruber, F X; Stenke, L; Eriksson, K M; Markevärn, B; Lübking, A; Vestergaard, H; Udby, L; Bjerrum, O W; Persson, I; Mustjoki, S; Olsson-Strömberg, U

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Hjorth-Hansen, H; Stentoft, J; Richter, J; Koskenvesa, P; Höglund, M; Dreimane, A; Porkka, K; Gedde-Dahl, T; Gjertsen, B T; Gruber, F X; Stenke, L; Eriksson, K M; Markevärn, B; Lübking, A; Vestergaard, H; Udby, L; Bjerrum, O W; Persson, I; Mustjoki, S; Olsson-Strömberg, U.

Affiliation

Hjorth-Hansen H; Department of Hematology, St Olavs Hospital, Trondheim, Norway.
Stentoft J; Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Richter J; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Koskenvesa P; Department of Hematology and Vascular Disorders, Skåne University Hospital, Lund, Sweden.
Höglund M; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Dreimane A; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden.
Porkka K; Department of Medical and Health Sciences, Linköping University, Department of Hematology, County Council of Östergötland, Linköping, Sweden.
Gedde-Dahl T; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Gjertsen BT; Department of Hematology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
Gruber FX; Department of Internal Medicine, Hematology Section, Haukeland University Hospital and Department of Clinical Science, University of Bergen, Bergen, Norway.
Stenke L; Department of Hematology, University Hospital of North Norway, Tromsø, Norway.
Eriksson KM; Department of Hematology, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden.
Markevärn B; Department of Internal Medicine, Sunderbysjukhuset, Luleå, Sweden.
Lübking A; Department of Hematology, Umeå University Hospital, Umeå, Sweden.
Vestergaard H; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.
Udby L; Department of Hematology, Odense University Hospital, Odense, Denmark.
Bjerrum OW; Department of Hematology, Roskilde Hospital, Roskilde, Denmark.
Persson I; Department of Hematology, Rigshospitalet, University Hospital of Copenhagen, Copenhagen, Denmark.
Mustjoki S; Department of Statistics, Uppsala University, Uppsala, Sweden.
Olsson-Strömberg U; Hematology Research Unit Helsinki, University of Helsinki and Department of Hematology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland.

Leukemia ; 30(9): 1853-60, 2016 09.

Article de En | MEDLINE | ID: mdl-27133821

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Polyéthylène glycols / Leucémie myéloïde en phase chronique / Protocoles de polychimiothérapie antinéoplasique / Interféron alpha / Dasatinib Type d'étude: Clinical_trials / Diagnostic_studies Limites: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Leukemia Sujet du journal: HEMATOLOGIA / NEOPLASIAS Année: 2016 Type de document: Article Pays d'affiliation: Norvège

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google